GENO Stock Overview
Develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Genovis AB (publ.) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 25.00 |
| 52 Week High | SEK 53.90 |
| 52 Week Low | SEK 19.00 |
| Beta | 1.65 |
| 1 Month Change | -10.87% |
| 3 Month Change | 8.70% |
| 1 Year Change | -51.92% |
| 3 Year Change | -62.24% |
| 5 Year Change | 2.04% |
| Change since IPO | -76.64% |
Recent News & Updates
Recent updates
Genovis AB (publ.)'s (STO:GENO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Sep 19
Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings
Aug 28Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts
Aug 23The Genovis AB (publ.) (STO:GENO) Analysts Have Been Trimming Their Sales Forecasts
Aug 21Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Aug 12Genovis AB (publ.)'s (STO:GENO) 36% Jump Shows Its Popularity With Investors
May 31This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate
May 09Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models
Apr 26Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Mar 18What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash
Feb 28We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings
Feb 22These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts
Feb 20Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be
Feb 04Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors
Oct 06Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?
Jun 22What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?
May 13Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?
Dec 22Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?
Nov 14If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity
Jul 08Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?
Jun 01Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%
May 10One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically
Feb 10Is Now The Time To Put Genovis AB (publ.) (STO:GENO) On Your Watchlist?
Aug 09Shareholder Returns
| GENO | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | -1.2% | -1.9% | -1.6% |
| 1Y | -51.9% | 16.5% | 6.5% |
Return vs Industry: GENO underperformed the Swedish Life Sciences industry which returned 12.7% over the past year.
Return vs Market: GENO underperformed the Swedish Market which returned 6.1% over the past year.
Price Volatility
| GENO volatility | |
|---|---|
| GENO Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 7.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: GENO's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: GENO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 32 | Fredrik Olsson | www.genovis.com |
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease.
Genovis AB (publ.) Fundamentals Summary
| GENO fundamental statistics | |
|---|---|
| Market cap | SEK 1.64b |
| Earnings (TTM) | SEK 27.91m |
| Revenue (TTM) | SEK 130.57m |
58.6x
P/E Ratio12.5x
P/S RatioIs GENO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENO income statement (TTM) | |
|---|---|
| Revenue | SEK 130.57m |
| Cost of Revenue | SEK 15.13m |
| Gross Profit | SEK 115.44m |
| Other Expenses | SEK 87.53m |
| Earnings | SEK 27.91m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | 0.43 |
| Gross Margin | 88.41% |
| Net Profit Margin | 21.38% |
| Debt/Equity Ratio | 0% |
How did GENO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 05:02 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genovis AB (publ.) is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Albin | Danske Bank |
| Simon Larsson | Danske Bank |
| Josefine Persson | Nordea Markets |